Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Public ClinicalTrials.gov record NCT00719264. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.
Study identification
- NCT ID
- NCT00719264
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 365 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 12, 2008 (Actual)
- Primary completion
- Dec 31, 2011 (Actual)
- Completion
- Apr 15, 2013 (Actual)
- Last update posted
- Mar 20, 2017
2008 – 2013
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group Dept of Highlands Oncology Grp | Fayetteville | Arkansas | 72703 | — |
| City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(3) | Duarte | California | 91010-3000 | — |
| USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3 | Los Angeles | California | 90053 | — |
| University of California at Los Angeles Dept. of Hem/Oncology | Los Angeles | California | 90095 | — |
| Karmanos Cancer Institute Dept.of KarmanosCancerInst (5) | Detroit | Michigan | 48201 | — |
| Nevada Cancer Institute Dept. of Nevada Cancer (3) | Las Vegas | Nevada | 89135 | — |
| St. Luke's Hospital and Health Network St. Luke's Cancer Network | Bethlehem | Pennsylvania | — | — |
| Las Colinas Hematology Oncology Grapevine | Irving | Texas | 75038 | — |
| Seattle Cancer Care Alliance Dept. of SCCA | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 100 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00719264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 20, 2017 · Synced Nov 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00719264 live on ClinicalTrials.gov.